O
Ouro Medicines
Biotechnology firm advancing immune reset therapeutics for chronic immune-mediated diseases with a robust clinical pipeline
About Ouro Medicines
Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics aimed at treating chronic immune-mediated diseases. The company operates in the biopharmaceutical sector, targeting patients who suffer from conditions that involve the immune system. Ouro Medicines leverages its scientific expertise and a strong track record in advancing cell-depleting therapies through clinical stages. The business model revolves around research and development, with a significant portion of its funding directed towards creating novel T cell engagers that have the potential to reset the immune system. Ouro Medicines generates revenue through partnerships and collaborations, as well as through the development and commercialization of its therapeutic assets. The company was founded by Monograph Capital in collaboration with GSK and has secured substantial funding from investors such as TPG, NEA, and Norwest. With a promising clinical stage asset and a robust discovery pipeline, Ouro Medicines is positioned to redefine treatment paradigms for immune-mediated diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2024
- Headquarters
- South San Francisco, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 89.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Autoimmune, Immune System, Immunotherapy, Became $1B as Subsidiary, Biotech and Pharma, Cell Therapy, T Cell, DT and LS
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2026 | $1.7B | $1.7B | Gilead Sciences | ↗ |
| SERIES AOther financing | Jan 2025 | $120M | $480M | UPMC Enterprises · TPG · NEA · Norwest Venture Partners | ↗ |
Growth signals
Latest recorded traffic for Ouro Medicines is 5.1K monthly website visits, up 82.1% over the last three months. Ouro Medicines's team grew 8.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
TPG
NEA
Norwest Venture Partners
UPMC Enterprises
GSK
Zoo Capital
Monograph Capital
LongRiver Investments
Other known investors1 additional known investor
Gilead Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ouro Medicines on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ouro Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.